{
  "docId": "019de075-89b3-76e0-854f-751e522d63c5",
  "docSlug": "a1e66a21a5f72ac122dd8f79d63b40d9",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 39,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide outlines a sequential clinical trial process.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-89b3-76e0-854f-751e522d63c5/33",
  "deckHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5",
  "deckJsonHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5.json",
  "deckAnchorHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.038
      },
      "kind": "diagram",
      "text": "Single Ascending Dose -> Multiple Ascending Dose -> Proof-of-Concept Study in Celiac Disease Patients",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41c32ecc-26c0-4803-8ba0-4c5b4d44a7ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.35,
        "y": 0.065
      },
      "kind": "list",
      "text": "Secondary Objectives SAD & MAD: pharmacokinetics (PK) and pharmacodynamics (PD) of EQ102",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25eb20f1-4154-4090-a6ed-ef6eac91e57e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.065
      },
      "kind": "list",
      "text": "Primary Objective SAD & MAD: safety and tolerability of EQ102 after single and multiple ascending doses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5195b5c8-a7df-431e-8efd-09a65f3a503f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.68,
        "y": 0.065
      },
      "kind": "list",
      "text": "Objective Celiac Disease Patients: Efficacy signal in patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ee3e6bc-a6fc-4f22-8187-f99253005a0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.75,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "Randomized, double-blinded, controlled SAD/MAD study, followed by proof-of-concept evaluation in patients with celiac disease",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d985b650-96ac-43e4-9151-5f83f6707731",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.12,
        "y": 0.094
      },
      "kind": "source-note",
      "text": "SAD = single ascending dose; MAD = multiple ascending dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f2f467e-2f8c-4103-8089-2b337aeb5446",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.04,
        "y": 0.07
      },
      "kind": "title",
      "text": "Phase 1 First-in-Human Study of EQ102",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e029fb6b-4eee-43aa-8adf-78418353a932",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "01f124c2-c661-4fc1-967e-05062859089a",
      "evidence": "Sequential flow of clinical trial phases",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 33,
      "from": 32,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "9dba4129-78e2-4c77-b498-89d21b1c341b",
      "evidence": "The deck presents information on the potential for EQ102 in celiac disease",
      "position": 1,
      "objective": "Highlight the potential for EQ102 to be a differentiated asset in celiac disease",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}